Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$110.7 million.

  • Crinetics Pharmaceuticals' Cash from Operations fell 7623.8% to -$110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$347.7 million, marking a year-over-year decrease of 7225.1%. This contributed to the annual value of -$226.0 million for FY2024, which is 3587.52% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Cash from Operations of -$110.7 million as of Q3 2025, which was down 7623.8% from -$85.9 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash from Operations registered a high of -$13.5 million during Q1 2022, and its lowest value of -$110.7 million during Q3 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Cash from Operations value was -$40.7 million (recorded in 2023), while the average stood at -$46.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 3251.11% in 2022, then plummeted by 20065.72% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Operations (Quarter) stood at -$22.9 million in 2021, then crashed by 53.75% to -$35.2 million in 2022, then dropped by 9.4% to -$38.5 million in 2023, then crashed by 62.66% to -$62.6 million in 2024, then tumbled by 76.73% to -$110.7 million in 2025.
  • Its Cash from Operations stands at -$110.7 million for Q3 2025, versus -$85.9 million for Q2 2025 and -$88.5 million for Q1 2025.